Citigroup
GENB

Citigroup’s Generate Biomedicines GENB Stock Holding History

Citigroup’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.1K Buy
+2,244
New +$27.4K ﹤0.01% 4728

Other funds holding GENB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Citigroup's GENB Position: Q1 2026 in Review

Citigroup opened a new position in Generate Biomedicines (GENB) in Q1 2026: 2,244 shares worth $28.1K. The stake represents ﹤0.01% of the portfolio and ranks #4728 among its holdings.

57 funds tracked by Wall St. Rank hold GENB as of Q1 2026.

  • Citigroup held 2,244 shares of Generate Biomedicines worth $28.1K as of Q1 2026.
  • Generate Biomedicines was a new Citigroup position in Q1 2026.
  • Generate Biomedicines made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4728 holding.
  • 57 funds tracked by Wall St. Rank held Generate Biomedicines as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.